Razavi International Journal of Medicine

Published by: Kowsar

The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231

Aliasghar Rahimian 1 and Ali Mellati 1 , *
Authors Information
1 Department of Biochemistry, Zanjan University of Medical Sciences, Zanjan, Iran
Article information
  • Razavi International Journal of Medicine: June 2017, 5 (2); e55455
  • Published Online: June 21, 2017
  • Article Type: Research Article
  • Received: November 5, 2016
  • Revised: January 7, 2017
  • Accepted: January 17, 2017
  • DOI: 10.5812/rijm.55455

To Cite: Rahimian A, Mellati A. The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231, Razavi Int J Med. 2017 ; 5(2):e55455. doi: 10.5812/rijm.55455.

Abstract
Copyright © 2017, Razavi International Journal of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012; 156(9): 635-48[DOI][PubMed]
  • 2. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23(29): 7350-60[DOI][PubMed]
  • 3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16): 5367-74[DOI][PubMed]
  • 4. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19(2): 264-71[DOI][PubMed]
  • 5. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010; 4: 35-41[PubMed]
  • 6. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009; 7(1-2): 4-13[DOI][PubMed]
  • 7. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472): 1687-717[DOI][PubMed]
  • 8. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1): 39-51[DOI][PubMed]
  • 9. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15): 2568-81[DOI][PubMed]
  • 10. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10(1): 32-42[DOI][PubMed]
  • 11. Sarkar S, Longacre M, Tatur N, Heerboth S, Lapinska K. Histone deacetylases (HDACs): Function, mechanism, & inhibition. Encyclopedia Analytical Chem. 2014;
  • 12. Zentner GE, Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol. 2013; 20(3): 259-66[DOI][PubMed]
  • 13. Ahmad K, Henikoff S. Epigenetic consequences of nucleosome dynamics. Cell. 2002; 111(3): 281-4[PubMed]
  • 14. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo). 1990; 43(12): 1524-32[PubMed]
  • 15. Hoshikawa Y, Kijima M, Yoshida M, Beppu T. Expression of differentiation-related markers in teratocarcinoma cells via histone hyperacetylation by trichostatin A. Agricultural Biological Chem. 1991; 55(6): 1491-5
  • 16. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res. 1994; 214(1): 189-97[DOI][PubMed]
  • 17. Sugita K, Koizumi K, Yoshida H. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res. 1992; 52(1): 168-72[PubMed]
  • 18. Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (Tokyo). 1990; 43(9): 1101-6[PubMed]
  • 19. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 1987; 47(14): 3688-91[PubMed]
  • 20. Yoshida M, Beppu T. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Experimental Cell Res. 1988; 177(1): 122-31[DOI]
  • 21. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997; 57(17): 3697-707[PubMed]
  • 22. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37): 5420-32[DOI][PubMed]
  • 23. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009; 274(2): 169-76[DOI][PubMed]
  • 24. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem. 2004; 11(12): 1629-43[PubMed]
  • 25. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010; 32(1-2): 35-48[DOI][PubMed]
  • 26. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007; 16(5): 659-78[DOI][PubMed]
  • 27. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007; 7(4): 583-98[DOI][PubMed]
  • 28. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18): 10393-8[DOI][PubMed]
  • 29. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21): 2492-502[DOI][PubMed]
  • 30. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004; 64(3): 830-5[PubMed]
  • 31. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006; 59(7): 729-35[DOI][PubMed]
  • 32. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006; 42(18): 3149-56[DOI][PubMed]
  • 33. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9(1)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments